Effect of metoprolol on cardiac and pulmonary function in chronic obstructive pulmonary disease

Paul E Fenster, F. M. Hasan, T. Abraham, J. Woolfenden

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

We evaluated the effects of oral metoprolol, 200 mg daily, on cardiac and pulmonary function in 6 patients with chronic reversible airways obstruction and no cardiac dysfunction. The patients were clinically stable. In all patients, baseline forced expiratory volume in 1 second (FEV1) was less than 60% predicted, and increased at least 15% after isoproterenol inhalation. Resting control first pass right and left ventricular radionuclide ejection fractions were normal or only slightly depressed. Compared to placebo, metoprolol did not significantly affect FEV1 or forced vital capacity. Metoprolol did not significantly alter left or right ventricular ejection fraction, measured by first pass radionuclide technique. One patient experienced increased dyspnea on metoprolol, which was not accompanied by changes in clinical exam, spirometry, or ejection fraction. We conclude that metoprolol may be safely administered to a subset of stable patients with chronic reactive airways disease.

Original languageEnglish (US)
Pages (from-to)125-129
Number of pages5
JournalClinical Cardiology
Volume6
Issue number3
StatePublished - 1983

Fingerprint

Metoprolol
Chronic Obstructive Pulmonary Disease
Lung
Forced Expiratory Volume
Radioisotopes
Stroke Volume
Spirometry
Vital Capacity
Airway Obstruction
Isoproterenol
Dyspnea
Inhalation
Placebos

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Effect of metoprolol on cardiac and pulmonary function in chronic obstructive pulmonary disease. / Fenster, Paul E; Hasan, F. M.; Abraham, T.; Woolfenden, J.

In: Clinical Cardiology, Vol. 6, No. 3, 1983, p. 125-129.

Research output: Contribution to journalArticle

Fenster, Paul E ; Hasan, F. M. ; Abraham, T. ; Woolfenden, J. / Effect of metoprolol on cardiac and pulmonary function in chronic obstructive pulmonary disease. In: Clinical Cardiology. 1983 ; Vol. 6, No. 3. pp. 125-129.
@article{92b05bb11a88431c82790b4e1955f9e1,
title = "Effect of metoprolol on cardiac and pulmonary function in chronic obstructive pulmonary disease",
abstract = "We evaluated the effects of oral metoprolol, 200 mg daily, on cardiac and pulmonary function in 6 patients with chronic reversible airways obstruction and no cardiac dysfunction. The patients were clinically stable. In all patients, baseline forced expiratory volume in 1 second (FEV1) was less than 60{\%} predicted, and increased at least 15{\%} after isoproterenol inhalation. Resting control first pass right and left ventricular radionuclide ejection fractions were normal or only slightly depressed. Compared to placebo, metoprolol did not significantly affect FEV1 or forced vital capacity. Metoprolol did not significantly alter left or right ventricular ejection fraction, measured by first pass radionuclide technique. One patient experienced increased dyspnea on metoprolol, which was not accompanied by changes in clinical exam, spirometry, or ejection fraction. We conclude that metoprolol may be safely administered to a subset of stable patients with chronic reactive airways disease.",
author = "Fenster, {Paul E} and Hasan, {F. M.} and T. Abraham and J. Woolfenden",
year = "1983",
language = "English (US)",
volume = "6",
pages = "125--129",
journal = "Clinical Cardiology",
issn = "0160-9289",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Effect of metoprolol on cardiac and pulmonary function in chronic obstructive pulmonary disease

AU - Fenster, Paul E

AU - Hasan, F. M.

AU - Abraham, T.

AU - Woolfenden, J.

PY - 1983

Y1 - 1983

N2 - We evaluated the effects of oral metoprolol, 200 mg daily, on cardiac and pulmonary function in 6 patients with chronic reversible airways obstruction and no cardiac dysfunction. The patients were clinically stable. In all patients, baseline forced expiratory volume in 1 second (FEV1) was less than 60% predicted, and increased at least 15% after isoproterenol inhalation. Resting control first pass right and left ventricular radionuclide ejection fractions were normal or only slightly depressed. Compared to placebo, metoprolol did not significantly affect FEV1 or forced vital capacity. Metoprolol did not significantly alter left or right ventricular ejection fraction, measured by first pass radionuclide technique. One patient experienced increased dyspnea on metoprolol, which was not accompanied by changes in clinical exam, spirometry, or ejection fraction. We conclude that metoprolol may be safely administered to a subset of stable patients with chronic reactive airways disease.

AB - We evaluated the effects of oral metoprolol, 200 mg daily, on cardiac and pulmonary function in 6 patients with chronic reversible airways obstruction and no cardiac dysfunction. The patients were clinically stable. In all patients, baseline forced expiratory volume in 1 second (FEV1) was less than 60% predicted, and increased at least 15% after isoproterenol inhalation. Resting control first pass right and left ventricular radionuclide ejection fractions were normal or only slightly depressed. Compared to placebo, metoprolol did not significantly affect FEV1 or forced vital capacity. Metoprolol did not significantly alter left or right ventricular ejection fraction, measured by first pass radionuclide technique. One patient experienced increased dyspnea on metoprolol, which was not accompanied by changes in clinical exam, spirometry, or ejection fraction. We conclude that metoprolol may be safely administered to a subset of stable patients with chronic reactive airways disease.

UR - http://www.scopus.com/inward/record.url?scp=0020676640&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020676640&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 125

EP - 129

JO - Clinical Cardiology

JF - Clinical Cardiology

SN - 0160-9289

IS - 3

ER -